Danaher Co. (NYSE:DHR) Shares Purchased by Dillon & Associates Inc.

Dillon & Associates Inc. lifted its holdings in shares of Danaher Co. (NYSE:DHR) by 3.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 49,740 shares of the conglomerate’s stock after purchasing an additional 1,564 shares during the quarter. Danaher comprises approximately 1.9% of Dillon & Associates Inc.’s investment portfolio, making the stock its 16th biggest position. Dillon & Associates Inc.’s holdings in Danaher were worth $13,828,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DHR. Benjamin Edwards Inc. grew its stake in shares of Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after buying an additional 38 shares in the last quarter. Wedge Capital Management L L P NC lifted its stake in shares of Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after buying an additional 38 shares during the last quarter. Patrick M Sweeney & Associates Inc. raised its holdings in Danaher by 3.4% in the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after acquiring an additional 40 shares during the period. Trust Co of Kansas increased its stake in shares of Danaher by 4.1% in the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after purchasing an additional 40 shares during the period. Finally, Abacus Planning Group Inc. boosted its position in shares of Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after acquiring an additional 40 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DHR has been the subject of several research analyst reports. Wells Fargo & Company initiated coverage on shares of Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price for the company. Bank of America raised their target price on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Royal Bank of Canada reduced their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Evercore ISI boosted their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Stifel Nicolaus upped their price objective on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $287.16.

Insider Activity

In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 10.90% of the stock is currently owned by company insiders.

Danaher Trading Down 1.5 %

NYSE DHR opened at $239.59 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12 month low of $193.75 and a 12 month high of $281.70. The company has a market capitalization of $173.05 billion, a PE ratio of 45.72, a P/E/G ratio of 4.47 and a beta of 0.85. The stock has a 50-day simple moving average of $264.37 and a 200 day simple moving average of $260.82.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.02 earnings per share. Research analysts forecast that Danaher Co. will post 7.51 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio is currently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.